Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients. Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study

Giuseppe G L Biondi-Zoccai, Giuseppe M. Sangiorgi, David Antoniucci, Eberhard Grube, Carlo Di Mario, Bernard Reimers, Corrado Tamburino, Pierfrancesco Agostoni, John Cosgrave, Antonio Colombo

Research output: Contribution to journalArticle

Abstract

Background: Paclitaxel-eluting stents (PES) have been proved effective in randomized trials enrolling highly selected patients. Yet, given the uncertainty concerning results of PES implantation in very high-risk patients and lesions, we designed a prospective multicenter registry, the Taxus in Real-life Usage Evaluation (TRUE) Study. Study design, patient characteristics and in-hospital outcomes: Consecutive patients undergoing PES implantation were enrolled provided that the target lesion treated with PES was an unprotected left main (ULM), a true bifurcation, a chronic total occlusion (CTO), a long lesion (> 28 mm), located in a small vessel (<2.75 mm), or the patient had diabetes mellitus. Clinical events will be adjudicated at 1, 7 and 12 months, with 4- to 8-month angiographic follow-up. The primary end-point will be the 7-month occurrence of major adverse cardiovascular events (MACE, i.e. the composite of cardiac death, non-fatal myocardial infarction [MI], coronary artery bypass grafting [CABG] and percutaneous target vessel revascularization [TVR]). To date, patient enrolment has been completed reaching the target of 1065 subjects. These included 322 (30.2%) diabetics, 115 (10.8%) subjects undergoing PES implantation for ULM, 229 (21.5%) in a bifurcation, 191 (17.9%) in a CTO, 430 (40.4%) in a small vessel, and 289 (27.1%) in a long lesion. An average of 1.5 ± 0.6 vessels and 2.0 ± 1.0 lesions were treated per patient, with 2.0 ± 1.2 PES implanted per patient, and a 46 ± 30 mm total PES length per patient. In-hospital MACE occurred in 39 (3.7%) patients, with 2 (0.2%) cardiac deaths, 32 (3.0%) MI, 5 (0.5%) TVR, no CABG, and 4 (0.4%) acute stent thromboses. Implications: Despite the availability of randomized trials, only carefully designed and prospective registries can provide timely and accurate assessment of the risk-benefit profile of PES in very high-risk patients. Indeed, the TRUE Study, including as much as 115 ULM and 229 bifurcation interventions, should give important insights into the outcome of PES in such an unprecedented and challenging context.

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalInternational Journal of Cardiology
Volume117
Issue number3
DOIs
Publication statusPublished - May 2 2007

Keywords

  • Coronary artery disease
  • Drug-eluting stent
  • Paclitaxel-eluting stent
  • Restenosis
  • Study design

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Testing prospectively the effectiveness and safety of paclitaxel-eluting stents in over 1000 very high-risk patients. Design, baseline characteristics, procedural data and in-hospital outcomes of the multicenter Taxus in Real-life Usage Evaluation (TRUE) Study'. Together they form a unique fingerprint.

  • Cite this